Immunotherapy and targeted therapy plus chemo for extensive small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of three drugs—an immunotherapy (adebrelimab), a targeted therapy (famitinib), and chemotherapy—for people with extensive-stage small cell lung cancer. The goal is to see if this triple combination works better than standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with extensive-stage small cell lung cancer (cancer that has spread widely).
- You have not yet received any treatment for this cancer (like chemotherapy).
- You are fully independent or mostly independent in daily activities (ECOG performance status 0 or 1).
- Your major organs (heart, liver, kidneys, etc.) are working well enough to receive the study drugs.
- If you could become pregnant or father a child, you must agree to use effective birth control during treatment and for 6 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, adebrelimab and irinotecan liposome, with or without a third drug called famitinib, for people with extensive-stage small cell lung cancer that has progressed after initial treatment with immunotherapy. The goal is to see if this combination can help control the cancer.
This trial tests a new combination of an immunotherapy drug (adebelimab) with chemotherapy as a first treatment for extensive-stage small cell lung cancer. It aims to see if this combination can help control the cancer better than standard care.
This trial tests a new combination treatment for extensive-stage small cell lung cancer: intensive chemotherapy plus an immunotherapy drug (adebrelimab), followed by a stem cell transplant using your own cells. The goal is to see if this powerful approach can shrink tumors and help you live longer.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and chest radiation for people with extensive-stage small cell lung cancer (SCLC) that has spread. The goal is to see if this combination helps shrink or control the cancer longer.
This trial tests a combination of two immunotherapy drugs (sintilimab and tafolecimab) plus standard chemotherapy as a first treatment for extensive-stage small cell lung cancer. The goal is to see if adding these drugs helps people live longer and have better outcomes.
This trial tests a combination of an immunotherapy drug (adebrelimab), chemotherapy, and radiation therapy as a first treatment for extensive-stage small cell lung cancer. The goal is to see if this combination helps people live longer and feel better.
Hear when a new Small Cell Lung Cancer Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.